A Phase 1, Open-label, Single Dose, Parallel-group Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Renal Function

Trial Profile

A Phase 1, Open-label, Single Dose, Parallel-group Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Jun 2016 Status changed from recruiting to completed.
    • 23 Dec 2014 Planned End Date changed from 1 Jun 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 01 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2016 to 1 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top